Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

3.51 

-0.02 -0.4%

as of Mar 22 '19

52 Week Range:

2.90 3.95


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Faes Farma, S.A., a pharmaceutical company, develops, produces and commercializes pharmaceutical products and raw materials primarily in Spain and Portugal. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Colme to treat chronic alcoholism; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it offers sitagliptine, and sitagliptine and metformine products to treat diabetes type-II; Hidroferol; Acoxxel; Diosmin and Micronized Diosmin for chronic venous insufficiency; Sulbutiamine to treat asthenia, concentration, and memory deficit; Arginine Aspartate; and swine feeding products. It also exports its products approximately to 60 countries. Faes Farma, S.A. was founded in 1933 and is headquartered in Madrid, Spain.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 0.75
0.90
0.92
0.83
0.90
0.91
growth rate 20.0% 2.2% -9.8% 8.4% 1.1%
Earnings BIT 17.95
11.92
19.46
12.38
19.25
28.61
35.85
41.34
47.82
49.07
62.01
growth rate -33.6% 63.3% -36.4% 55.5% 48.6% 25.3% 15.3% 15.7% 2.6% 26.4%
Avg.PE 24.45
35.34
26.53
17.92
17.12
25.38
20.87
17.78
17.60
growth rate 44.5% -24.9% -32.5% -4.5% 48.3% -6.3% -14.8% -1.0%
ROA 7.20
7.10
7.50
4.80
6.80
7.90
growth rate -1.4% 5.6% -36.0% 41.7% 16.2%
ROE 12.70
13.00
13.90
8.50
11.10
11.80
growth rate 2.4% 6.9% -38.9% 30.6% 6.3%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 35.71
36.17
37.85
33.27
41.51
38.87
42.24
46.26
49.06
76.25
81.54
growth rate 1.3% 4.6% -12.1% 24.8% -6.4% 8.7% 9.5% 6.1% 55.4% 6.9%
Acct.Payable 16.27
16.40
16.98
19.04
30.96
35.64
growth rate 0.8% 3.6% 12.1% 62.7% 15.1%
Cur.Assets 80.13
86.99
87.71
83.56
82.89
85.04
88.68
113.47
153.66
169.83
growth rate 8.6% 0.8% -4.7% -0.8% 2.6% 4.3% 28.0% 35.4% 10.5%
Total Assets 219.30
293.00
297.10
291.10
286.80
273.82
267.23
290.68
331.22
429.50
growth rate 33.6% 1.4% -2.0% -1.5% -4.5% -2.4% 8.8% 14.0% 29.7%
Cash 0.40
9.40
2.20
6.10
4.90
7.97
6.72
25.55
58.82
43.27
growth rate 2,250.0% -76.6% 177.3% -19.7% 62.6% -15.7% 280.3% 130.2% -26.4%
Inventory 27.45
29.53
36.19
32.54
30.46
31.09
32.91
34.03
38.29
49.87
growth rate 7.6% 22.6% -10.1% -6.4% 2.1% 5.8% 3.4% 12.5% 30.2%
Cur.Liabilities 65.88
67.52
81.50
74.88
52.89
51.25
30.07
31.10
37.95
56.45
growth rate 2.5% 20.7% -8.1% -29.4% -3.1% -41.3% 3.5% 22.0% 48.8%
Liabilities 99.30
130.20
131.60
123.50
102.00
76.02
38.61
36.34
46.34
109.47
growth rate 31.1% 1.1% -6.2% -17.4% -25.5% -49.2% -5.9% 27.5% 136.3%
LT Debt 26.40
42.80
32.10
33.50
34.70
20.52
5.31
1.19
44.43
4.12
growth rate 62.1% -25.0% 4.4% 3.6% -40.9% -74.1% -52.6% 3,624.1% -90.7%
Equity 120.00
162.80
165.50
167.60
184.80
197.80
228.62
254.33
284.88
319.50
growth rate 35.7% 1.7% 1.3% 10.3% 7.0% 15.6% 11.2% 12.0% 12.2%
Common Shares 160.05
180.06
219.94
202.79
204.82
21.98
23.50
24.79
25.50
26.16
growth rate 12.5% 22.2% -7.8% 1.0% -89.3% 6.9% 5.5% 2.8% 2.6%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 4.10
4.10
3.60
1.80
0.50
0.73
2.42
9.85
10.78
12.09
growth rate 0.0% -12.2% -50.0% -72.2% 45.0% 233.1% 307.7% 9.5% 12.1%
Cash Dividends 13.50
15.20
16.80
7.80
6.10
0.65
0.96
4.82
5.30
6.28
growth rate 12.6% 10.5% -53.6% -21.8% -89.4% 48.6% 402.2% 9.9% 18.5%
Cash From OA 24.90
22.40
15.20
20.00
23.90
31.65
32.26
40.91
49.63
41.73
growth rate -10.0% -32.1% 31.6% 19.5% 32.4% 1.9% 26.8% 21.3% -15.9%
Sale Purchase of Stock 0.13
0.13
0.16
growth rate 0.0% 17.2%
FCF 11.50
11.40
11.10
11.90
21.10
30.92
29.84
31.07
38.84
29.64
growth rate -0.9% -2.6% 7.2% 77.3% 46.6% -3.5% 4.1% 25.0% -23.7%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 131.60
195.30
202.50
190.20
176.10
193.32
198.06
214.24
236.86
282.16
growth rate 48.4% 3.7% -6.1% -7.4% 9.8% 2.5% 8.2% 10.6% 19.1%
Op.Income 8.60
25.40
19.50
12.40
19.30
28.61
35.85
41.34
47.82
49.07
62.01
growth rate 195.4% -23.2% -36.4% 55.7% 48.2% 25.3% 15.3% 15.7% 2.6% 26.4%
IBT 12.60
20.00
19.50
12.40
19.30
24.20
32.75
39.23
46.07
49.50
growth rate 58.7% -2.5% -36.4% 55.7% 25.4% 35.4% 19.8% 17.4% 7.5%
Net Income 18.20
21.30
20.00
14.20
19.50
22.61
25.33
30.36
36.59
41.38
growth rate 17.0% -6.1% -29.0% 37.3% 15.9% 12.1% 19.8% 20.5% 13.1%
EPS 0.11
0.11
0.10
0.07
0.09
0.10
growth rate 0.0% -9.1% -30.0% 28.6% 11.1%
Gross Profit 67.20
115.90
115.30
118.10
114.00
124.42
129.85
140.67
156.87
182.66
215.61
growth rate 72.5% -0.5% 2.4% -3.5% 9.1% 4.4% 8.3% 11.5% 16.4% 18.0%
R&D 1.30
1.30
1.40
1.40
1.38
growth rate 0.0% 7.7% 0.0% -1.6%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 10.50
15.80
16.92
13.88
15.41
growth rate 50.6% 7.1% -17.9% 11.0%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 76.25
88.27
81.54
growth rate 7.6% -3.9%
Acct.Payable 30.96
32.11
35.64
growth rate 1.8% 5.4%
Cur.Assets 169.83
205.38
growth rate 10.0%
Total Assets 430.24
466.34
growth rate 4.1%
Cash 43.27
57.49
growth rate 15.3%
Inventory 49.87
59.55
growth rate 9.3%
Cur.Liabilities 56.45
109.25
growth rate 39.1%
Liabilities 109.47
122.44
growth rate 5.8%
LT Debt 42.76
4.25
4.12
growth rate -68.5% -1.5%
Equity 320.24
320.24
343.29
343.29
growth rate 0.0% 7.2% 0.0%
Common Shares 26.16
27.01
growth rate 1.6%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures
growth rate
Cash Dividends
growth rate
Cash From OA
growth rate
FCF
growth rate
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 81.86
86.20
88.95
76.65
growth rate 5.3% 3.2% -13.8%
Op.Income 10.50
15.80
16.92
13.88
15.41
growth rate 50.6% 7.1% -17.9% 11.0%
IBT 10.93
15.70
17.21
13.59
growth rate 43.7% 9.6% -21.0%
Net Income 9.42
13.70
15.44
12.66
growth rate 45.5% 12.7% -18.0%
EPS
growth rate
Gross Profit 49.96
55.10
59.28
46.72
54.51
growth rate 10.3% 7.6% -21.2% 16.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (33.16)

YOY Growth Grade:

E (22.01)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 18.09 18.09 15.77
EPS / Growth 16.1% 0.19 6.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.4% 11.1% 11.1%
Future PE 12.80 18.71 18.71
Future EPS 0.36 0.56 0.56
Value Price
MOS %
1.14
-67.5%
2.58
-26.5%
2.58
-26.5%
MOS Price 0.57 1.29 1.29
IRT 11.87 9.79 9.79

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.